Matuzumab

DB05101

biotech investigational

Deskripsi

Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 196 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Matuzumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Matuzumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Matuzumab.
Estrone Estrone may increase the thrombogenic activities of Matuzumab.
Estradiol Estradiol may increase the thrombogenic activities of Matuzumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Matuzumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Matuzumab.
Mestranol Mestranol may increase the thrombogenic activities of Matuzumab.
Estriol Estriol may increase the thrombogenic activities of Matuzumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Matuzumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Matuzumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Matuzumab.
Tibolone Tibolone may increase the thrombogenic activities of Matuzumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Matuzumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Matuzumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Matuzumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Matuzumab.
Zeranol Zeranol may increase the thrombogenic activities of Matuzumab.
Equol Equol may increase the thrombogenic activities of Matuzumab.
Promestriene Promestriene may increase the thrombogenic activities of Matuzumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Matuzumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Matuzumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Matuzumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Matuzumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Matuzumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Matuzumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Matuzumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Matuzumab.
Formononetin Formononetin may increase the thrombogenic activities of Matuzumab.
Estetrol Estetrol may increase the thrombogenic activities of Matuzumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Matuzumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Matuzumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Matuzumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Matuzumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Matuzumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Matuzumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Matuzumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Matuzumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Matuzumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Matuzumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Matuzumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Matuzumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Matuzumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Matuzumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Matuzumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Matuzumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Matuzumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Matuzumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Matuzumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Matuzumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Matuzumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Matuzumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Matuzumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Matuzumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Matuzumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Matuzumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Matuzumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Matuzumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Matuzumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Matuzumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Matuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Matuzumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Matuzumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Matuzumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Matuzumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Matuzumab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Matuzumab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Matuzumab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Matuzumab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Matuzumab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Matuzumab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Matuzumab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Matuzumab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Matuzumab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Matuzumab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Matuzumab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Matuzumab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Matuzumab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Matuzumab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Matuzumab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Matuzumab is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Matuzumab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Matuzumab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Matuzumab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Matuzumab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Matuzumab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Canakinumab.

Target Protein

Epidermal growth factor receptor EGFR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18033688
    Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K: Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer. 2008 Apr 1;122(7):1530-8.
  • PMID: 17671148
    Socinski MA: Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4597-601.
  • PMID: 17126894
    Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F: A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007 Mar;104(3):727-31. Epub 2006 Nov 28.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul